C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

PURPOSE: Findings from the human epidermal growth factor receptor 2 (HER2) –positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients wi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Perez, Edith A., Jenkins, Robert B., Dueck, Amylou C., Wiktor, Anne E., Bedroske, Patrick P., Anderson, S. Keith, Ketterling, Rhett P., Sukov, William R., Kanehira, Kazunori, Chen, Beiyun, Geiger, Xochiquetzal J., Andorfer, Cathy A., McCullough, Ann E., Davidson, Nancy E., Martino, Silvana, Sledge, George W., Kaufman, Peter A., Kutteh, Leila A., Gralow, Julie R., Harris, Lyndsay N., Ingle, James N., Lingle, Wilma L., Reinholz, Monica M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2011
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3056653/
https://ncbi.nlm.nih.gov/pubmed/21245420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.2125
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items